CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has launched its “RNAi 2010” outlook for key scientific, clinical, and business initiatives as the company maintains its commitment to translating the science of RNAi into innovative medicines and building a leading biopharmaceutical company. The company also announced its product and business goals for 2008, the initiation of a development program, and updated its 2007 year-end cash position.
